Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Journey Medical (DERM) EBIT Margin (2020 - 2025)

Historic EBIT Margin for Journey Medical (DERM) over the last 6 years, with Q3 2025 value amounting to 8.67%.

  • Journey Medical's EBIT Margin rose 111100.0% to 8.67% in Q3 2025 from the same period last year, while for Sep 2025 it was 9.25%, marking a year-over-year increase of 219300.0%. This contributed to the annual value of 24.36% for FY2024, which is 217500.0% down from last year.
  • Per Journey Medical's latest filing, its EBIT Margin stood at 8.67% for Q3 2025, which was up 111100.0% from 19.16% recorded in Q2 2025.
  • Over the past 5 years, Journey Medical's EBIT Margin peaked at 49.93% during Q3 2023, and registered a low of 90.02% during Q2 2021.
  • Over the past 5 years, Journey Medical's median EBIT Margin value was 25.3% (recorded in 2025), while the average stood at 31.87%.
  • As far as peak fluctuations go, Journey Medical's EBIT Margin plummeted by -781300bps in 2021, and later soared by 1088300bps in 2023.
  • Over the past 5 years, Journey Medical's EBIT Margin (Quarter) stood at 51.7% in 2021, then fell by -21bps to 62.6% in 2022, then surged by 78bps to 13.79% in 2023, then soared by 219bps to 16.4% in 2024, then plummeted by -153bps to 8.67% in 2025.
  • Its EBIT Margin was 8.67% in Q3 2025, compared to 19.16% in Q2 2025 and 25.3% in Q1 2025.